The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic ...
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...
Stockhead on MSN11d
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trialRecce has opted to carry out its phase III diabetic foot injury trial in Indonesia - which looks a safer bet than the US ...
Zacks.com on MSN1d
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekOptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic ...
The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program ...
Acurx Pharmaceuticals, Inc. ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today ...
Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...
Ceftobiprole was turned down by the FDA in 2009 for ABSSSI when the drug was partnered with Johnson & Johnson’s Janssen Cilag unit. It has subsequently been approved as Zevtera or Mabelio in ...
acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia. Since more MRSA infections are resistant to traditional therapies now, Zevtera comes at a time when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback